Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...

Driven inflammatory disorders like asthma, chronic obstructive pulmonary disease, and atopic dermatitis, the cooperation centers on STAT6, a transcription factor associated with IL-4 and IL-13 ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

The development and commercialization deal zeros in on Leo’s preclinical STAT6 research programs, according to the Jan. 11 release. The transcription factor is used for IL-4 and IL-13 cytokine ...

In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program. Targeting STAT6 has ...

Gilead agreed to terms on a strategic partnership with LEO Pharma to accelerate the development and commercialization of STAT6, LEO’s small molecule oral program for treating patients with ...